SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq:EXEL) announced that Gisela Schwab, M.D., the company’s executive vice president and chief medical officer, will present at the Leerink Swann Cancer Roundtable Conference at 1:55 p.m. EDT / 10:55 a.m. PDT on Thursday, April 7, 2011, in New York. During the presentation, Dr. Schwab will review the most recent publicly available data for cabozantinib in castration-resistant prostate cancer (CRPC), discuss the pivotal trial plans and regulatory strategy for the compound in CRPC and provide a general business update.
The presentation will be webcast and may be accessed in the Event Calendar under Investors at www.exelixis.com.
Exelixis, Inc. is a biotechnology company committed to developing small molecule therapeutics for the treatment of cancer. Exelixis is focusing its resources and development efforts exclusively on cabozantinib, its most advanced solely-owned product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs. For more information, please visit the company’s web site at www.exelixis.com.
Charles Butler, 650-837-7277
Investor Relations and Corporate Communications
KEYWORDS: United States North America California New York
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Oncology Pharmaceutical Research FDA Science